Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Xilian Bai, Raymond Borrow*, Suzana Bukovski, Dominique A. Caugant, Davor Culic, Snezana Delic, Ener Cagri Dinleyici, Medeia Eloshvili, Tímea Erdősi, Jelena Galajeva, Pavla Křížová, Jay Lucidarme, Konstantin Mironov, Zuridin Nurmatov, Marina Pana, Erkin Rahimov, Larisa Savrasova, Anna Skoczyńska, Vinny Smith, Muhamed Kheir TahaLeonid Titov, Julio Vázquez, Lyazzat Yeraliyeva

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.

Original languageEnglish
Pages (from-to)528-541
Number of pages14
JournalJournal of Infection
Volume79
Issue number6
DOIs
Publication statusPublished - Dec 2019

Bibliographical note

Funding Information:
Authors would like to thank Dr Olivier Ronveaux (Infectious Hazard Management, World Health Organization, Geneva, Switzerland) for his contributions during this GMI Roundtable Meeting and for providing permission to use his presentation content in this manuscript. The authors were assisted in the preparation of the manuscript by Hannah Birchby, a professional medical writer at CircleScience, an Ashfield Company, part of UDG Healthcare plc. Medical writing support was funded by Sanofi Pasteur.

Funding Information:
Authors would like to thank Dr Olivier Ronveaux (Infectious Hazard Management, World Health Organization, Geneva, Switzerland) for his contributions during this GMI Roundtable Meeting and for providing permission to use his presentation content in this manuscript. The authors were assisted in the preparation of the manuscript by Hannah Birchby, a professional medical writer at CircleScience, an Ashfield Company, part of UDG Healthcare plc. Medical writing support was funded by Sanofi Pasteur.

Funding Information:
R Borrow, J Lucidarme and X Bai perform contract work for Public Health England on behalf of GSK, PATH, Sanofi Pasteur and Pfizer. EC Dinleyici performs contract work for the Eskisehir Osmangazi University funded by GSK, Sanofi Pasteur and Pfizer. A Skoczyńska has performed contract work for the National Medicines Institute funded by GSK and Pfizer, attended the Advisory Boards of GSK, Pfizer and Sanofi Pasteur and had personal fees from GSK, Pfizer and Sanofi Pasteur. V Smith represents Meningitis Research Foundation that receives grants from Sanofi Pasteur, GSK and Pfizer. MK Taha performs contract work for the Institut Pasteur funded by GSK, Pfizer and Sanofi Pasteur. JA Vázquez performs contract work for the Institute of Health Carlos III funded by GSK and Pfizer and he has received personal fees from GSK, Pfizer and Sanofi Pasteur. S Bukovski, DA Caugant, D Culic, S Delic, M Eloshvili, T Erdősi, J Galajeva, P Křížová, K Mironov, Z Nurmatov, M Pana, E Rahimov, L Savrasova, LP Titov and L Yeraliyeva have no conflicts of interest.

Publisher Copyright:
© 2019

Keywords

  • Antibiotic resistance
  • Bacterial meningitis
  • Conjugate vaccine
  • Eastern Europe
  • High-risk groups
  • Immunization program
  • Meningococcal disease
  • Neisseria meningitidis
  • Polysaccharide vaccine
  • Refugees

Fingerprint

Dive into the research topics of 'Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe'. Together they form a unique fingerprint.

Cite this